Next-Generation Sequencing (NGS) Diagnostics Market is expected to reach USD 44.8 billion by 2031

Next-generation sequencing (NGS) diagnostics Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the next-generation sequencing (NGS) platforms market will expand from USD 24.0 billion in 2026 to USD 44.8 billion in 2031 at a CAGR of 13.3% during the forecast period.

The next-generation sequencing (NGS) diagnostics market is rapidly evolving due to the rise in cancer cases, the rising need for high-precision diagnostic tools, and the ongoing evolution of genomic and molecular biology technologies. NGS makes it possible to analyze DNA on a large scale, which in turn makes it easy to detect diseases early, diagnose them, and identify mutations that can be acted upon to provide a specific treatment. Its use is seen in oncology, rare genetic diseases, infectious diseases, and reproductive health, as well as a foundation of modern diagnostics.

Request a free sample copy or view the report summary: Next-generation sequencing (NGS) diagnostics Market Report

Next-generation sequencing (NGS) diagnostics Market Report Highlights

• By Component Type, the rapidly increasing segment of the next-generation sequencing (NGS) diagnostics market will be Reagents and Kits. Their ubiquitous application across every stage of the sequencing workflow causes a steady demand for them at every NGS process, starting with sample preparation, library construction, and amplification. This demand is bound to expand further as NGS is more and more widely being used in clinical diagnostics, research laboratories, and so on. Also, the continued streamlining of reagent kits has led to an increase in high-quality, ready-to-use products that enhance the accuracy, sensitivity, and reproducibility of sequencing; hence, such products are essential to reliable genomic analysis.

• By Technology, directed sequencing is expected to show the highest growth rate since it is more cost-effective, has a faster turnaround time, and is clinically relevant as compared to other technologies. Targeted sequencing can be used to test a particular gene or a section of a gene with focused testing, applied when it is possible to predict the disease in relation to a gene whose activity is known to be involved in the disease, particularly in cancers and genetic tests. Also, specific sequencing can result in more targeted mutation detection and is favored by most clinical centers where time and actionable information are vital. The adoption of targeted sequencing is further aided by the development of improved panel designs and the development of improved sequencing methodologies.

• By Application, oncology will experience the highest growth rate mainly because of the rising cases of cancer in the world and the rising trend of precision therapeutics. The increasing need for early diagnosis, prognosis evaluation, and therapy monitoring is greatly driving the increase in the use of NGS in oncology.

• Infectious diseases are another rapidly expanding application segment, supported by the ability of NGS to identify and characterize a wide range of pathogens with high accuracy. It enables rapid detection of emerging and drug-resistant infections, making it a valuable tool in public health surveillance and outbreak management.

• Among regional segments, North America is expected to dominate the next-generation sequencing (NGS) diagnostics market, driven by its advanced healthcare infrastructure, strong presence of key industry players, and high adoption of cutting-edge genomic technologies. Favorable regulatory frameworks, increased funding for genomic research, and growing clinical integration of NGS-based diagnostics further support market growth in this region.

Next-generation sequencing (NGS) diagnostics Market Growth Drivers and Restraints

Growth Drivers:

• Rising Burden of Cancer and Genetic Disorders: The growing worldwide cancer and inherited disease cases are substantially contributing to the need for advanced genomic knowledge. To determine genetic mutations affecting disease progression and response to treatment, there is an increasing need to identify these mutations. Next-generation sequencing (NGS) provides an opportunity to analyze many genes simultaneously, which can be more comprehensively and accurately diagnosed than traditional methods.

• Shift Toward Precision Medicine: Healthcare systems are becoming less generalized in the treatment of various diseases and more personalized with biomarker-based treatment. NGS is highly important in this transition as it allows the determination of actionable genetic variants. This will enable clinicians to develop personal and specific treatment plans that will eventually enhance patient outcomes and treatment effectiveness.

Restraints:

• High Cost and Implementation Complexity: The broad use of next-generation sequencing (NGS) diagnostics is limited by the expensive nature of sequencing platforms, systems, and infrastructure deployment, and continued operational expenses. Moreover, data analysis and interpretation are complicated, and it demands highly qualified specialists and sophisticated bioinformatics. These can restrict adoption, especially in the resource-restricted healthcare environment and in new markets.

Next-generation sequencing (NGS) diagnostics Market Key Development

• Innovation: In February 2025, Illumina unveiled an 18-month innovation roadmap for its NovaSeq X sequencing system, enhancing output up to 35 billion reads, improving accuracy to Q70 quality scores, and increasing speed and workflow flexibility. These updates aim to broaden clinical applications in oncology, rare disease profiling, and high-throughput genomic studies by enabling faster runs and more sensitive detection.

Next-generation sequencing (NGS) diagnostics Market Segmentation

Knowledge Sourcing Intelligence has segmented the next-generation sequencing (NGS) diagnostics market based on component type, technology, application, and region:

Next-generation sequencing (NGS) diagnostics Market, By Component Type

• Instruments

• Reagents & Kits

• Software & Services

Next-generation sequencing (NGS) diagnostics Market, By Technology

• Whole Genome Sequencing

• Whole Exome Sequencing

• Targeted Sequencing

• RNA Sequencing

Next-generation sequencing (NGS) diagnostics Market, By Application

• Oncology

• Infectious Diseases

• Genetic Disorders

• Reproductive Health

• Pharmacogenomics

Next-generation sequencing (NGS) diagnostics Market, By Geography

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Next-generation sequencing (NGS) diagnostics Market Key Players

• Illumina

• Thermo Fisher Scientific

• Roche Diagnostics

• Agilent Technologies

• QIAGEN

• Bio-Rad Laboratories

• Danaher Corporation

• BGI Genomics

• Oxford Nanopore Technologies

• Pacific Biosciences